These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36737605)

  • 1. CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer.
    Son S; Kim H; Lim H; Lee JH; Lee KM; Shin I
    Cell Death Dis; 2023 Feb; 14(2):81. PubMed ID: 36737605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer.
    Huang YH; Chu PY; Chen JL; Huang CT; Huang CC; Tsai YF; Wang YL; Lien PJ; Tseng LM; Liu CY
    Sci Rep; 2021 Jun; 11(1):12171. PubMed ID: 34108545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.
    Han CL; Chen XR; Lan A; Hsu YL; Wu PS; Hung PF; Hung CL; Pan SH
    Cancer Sci; 2021 May; 112(5):1911-1923. PubMed ID: 33706413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
    Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
    Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells.
    Mukhopadhyay P; Lakshmanan I; Ponnusamy MP; Chakraborty S; Jain M; Pai P; Smith LM; Lele SM; Batra SK
    PLoS One; 2013; 8(2):e54455. PubMed ID: 23408941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
    Cheng W; Liu D; Guo M; Li H; Wang Q
    Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway.
    Sang R; Yu X; Xia H; Qian X; Yong J; Xu Y; Sun Y; Yao Y; Zhou J; Zhuo S
    Mol Carcinog; 2024 Apr; 63(4):785-796. PubMed ID: 38289126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
    Shome R; Ghosh SS
    Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
    Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.
    Wang Z; Ran X; Qian S; Hou H; Dong M; Wu S; Ding M; Zhang Y; Zhang X; Zhang M; Chen Q
    Arch Biochem Biophys; 2021 Oct; 710():108998. PubMed ID: 34280359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
    Bilir B; Kucuk O; Moreno CS
    J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.